肿瘤

订阅

MedSci主页 / 所有栏目 / 肿瘤

一表讲全！PD-1/PD-L1 免疫抑制剂使用宝典

2022-05-22 网络 网络

PD-1/PD-L1
关注

纯纯干货！

目前，靶向 PD-1/PD-L1 免疫检查点抑制剂已经在多种肿瘤中显示出不同凡响的临床疗效，但好药物还需正确、规范使用才能使患者获益。
 
本文小编整理一张表格（方便查找），总结了常见 PD-1/PD-L1 免疫抑制剂的使用注意事项，包括制备注意事项、用法用量、特殊人群剂量调整、输注注意事项等内容，供大家在临床工作中查验，期望能有所帮助。
 
图片

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852973, encodeId=0f0318529e350, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 29 11:27:53 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255159, encodeId=acc8125515901, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue May 24 10:27:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286309, encodeId=9fcd12863092e, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue May 24 10:27:53 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-07-29 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1852973, encodeId=0f0318529e350, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 29 11:27:53 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255159, encodeId=acc8125515901, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue May 24 10:27:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286309, encodeId=9fcd12863092e, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue May 24 10:27:53 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-05-24 smartjoy

    #PD-L1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1852973, encodeId=0f0318529e350, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jul 29 11:27:53 CST 2022, time=2022-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255159, encodeId=acc8125515901, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue May 24 10:27:53 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286309, encodeId=9fcd12863092e, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Tue May 24 10:27:53 CST 2022, time=2022-05-24, status=1, ipAttribution=)]
    2022-05-24 amy0550

    #免疫抑制剂#

    0

相关资讯

PD-1/L1竞争再加剧，中国生物制药与康方生物研发的治疗鼻咽癌新药上市申请获国家药监局受理

8月5日，康方生物发布公告称，与中国生物制药共同开发的PD-1单抗药物派安普利单抗已经向国家药监局提交新药上市申请，并获得受理。此次的适应症为三线治疗转移性鼻咽癌，也是派安普利在中国和美国成功提交的第

PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？

PD-1/PD-L1单抗治疗，用多久才能将药物疗效最大化？

中国肺癌临床研究的趋势：免疫治疗不能只关注PD-1/PD-L1

第九届中国肿瘤学临床试验发展论坛暨GACT/CTONG 2019年度会议在羊城广州隆重召开。会议前夕，【肿瘤资讯】对大会主席、广东省人民医院的吴一龙教授进行专访，介绍中国肺癌领域临床试验的发展变化特点及发展趋势。

中国肺癌临床研究趋势：免疫治疗不能只关注PD-1/PD-L1

2019年8月2-3日，第九届中国肿瘤学临床试验发展论坛暨GACT/CTONG 2019年度会议在羊城广州隆重召开。会议前夕，对大会主席、广东省人民医院的吴一龙教授进行专访，介绍中国肺癌领域临床试验的发展变化特点及发展趋势。

Cancer Immunol Res：肺癌免疫治疗研究领域取得新突破！

近年来，以PD-1/PD-L1为靶点的免疫治疗在晚期非小细胞肺癌（NSCLC）治疗的临床应用中取得了突破性进展，已成为继化疗、靶向治疗和抗血管生成治疗后另一重要的标准治疗策略。然而PD-1/PD-L1抑制剂单药治疗有效率并不高，在总体晚期NSCLC人群中仅为20%左右。尽管生物标志物指导下的精准免疫治疗可提高部分经选择患者的应答率，其获益人群仍然有限，进一步提高PD-1/PD-L1免疫治疗疗效仍是

一图读懂：国内批准的13款PD-1/PD-L1药物

PD-1/PD-L1中国适应证，看这篇就够了！